These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35275226)

  • 1. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats.
    Smith S; Sergio J; Coyle M; Elder K; Centner A; Cohen S; Terry M; Lipari N; Glinski J; Wheelis E; Budrow C; Bishop C
    Psychopharmacology (Berl); 2022 Jul; 239(7):2119-2132. PubMed ID: 35275226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
    Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
    Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
    Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
    Altwal F; Moon C; West AR; Steiner H
    Cells; 2020 Oct; 9(10):. PubMed ID: 33050305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia.
    Budrow C; Elder K; Coyle M; Centner A; Lipari N; Cohen S; Glinski J; Kinzonzi N; Wheelis E; McManus G; Manfredsson F; Bishop C
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
    Bishop C; George JA; Buchta W; Goldenberg AA; Mohamed M; Dickinson SO; Eissa S; Eskow Jaunarajs KL
    Eur J Neurosci; 2012 Sep; 36(6):2839-48. PubMed ID: 22762478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Chen YH; Kuo TT; Wang V; Cheng PW; Huang EY; Ma KH; Greig NH; Olson L; Hoffer BJ; Tseng KY
    J Parkinsons Dis; 2024; 14(5):941-964. PubMed ID: 38905058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
    Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
    Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
    Nevalainen N; Af Bjerkén S; Gerhardt GA; Strömberg I
    Neuroscience; 2014 Feb; 260():73-86. PubMed ID: 24361918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice.
    Ballardin D; Makrini-Maleville L; Seper A; Valjent E; Rebholz H
    Neurobiol Dis; 2024 Aug; 198():106559. PubMed ID: 38852753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
    Dupre KB; Ostock CY; Eskow Jaunarajs KL; Button T; Savage LM; Wolf W; Bishop C
    Exp Neurol; 2011 Jun; 229(2):288-99. PubMed ID: 21352823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.